Compound Guide

Semax

Semax after the April 15 FDA reclassification — the ACTH-analog peptide's Russian clinical history, research base, July PCAC timeline, and safety profile.

Last reviewed May 22, 2026

Quick Summary

What it is. Semax — a synthetic heptapeptide analog of adrenocorticotropic hormone fragment ACTH(4-10), stabilized by the addition of a C-terminal Pro-Gly-Pro tripeptide. Full sequence: Met-Glu-His-Phe-Pro-Gly-Pro. Developed and registered as a prescription drug in Russia since the 1990s.

Most-studied research areas. Neuroprotection in ischemic stroke, cognitive enhancement, BDNF and neurotrophin upregulation, Alzheimer’s disease models, spinal cord injury recovery, stress adaptation, and retinal neuroprotection.

Current U.S. legal status (May 2026). On April 15, 2026, the FDA removed Semax from Category 2 as part of a 12-peptide reclassification. It is now on an interim evaluation tier pending final 503A Bulks List placement at the July 23–24, 2026 PCAC meeting — one of seven peptides on that agenda. Licensed compounding pharmacies may legally fill prescriptions under a valid practitioner order.

Expected post-PCAC compounded price. $80–$160 per 5mg vial at a legitimate compounding pharmacy — comparable to DSIP due to its small size and well-characterized synthesis.

Evidence base. Semax has one of the deepest clinical histories of any peptide on the reclassification list, with decades of registered human use in Russia for stroke recovery and cognitive impairment. Preclinical research spans neuroprotection, neurotrophin signaling, gene expression, and blood-brain barrier penetration. Large-scale Western randomized controlled trials are absent — the evidence base is predominantly Russian-language clinical studies and international preclinical work.

What Is Semax?

Semax (CAS 80714-61-0) is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) — a rationally designed analog of ACTH(4-10), the shortest segment of adrenocorticotropic hormone that retains cognitive activity without steroidogenic (cortisol-stimulating) effects.

The key structural innovation is the C-terminal Pro-Gly-Pro (PGP) extension, added to enhance metabolic stability and blood-brain barrier penetration. Native ACTH(4-10) is rapidly degraded by peptidases; the PGP motif also contributes independent biological activity through N-formyl peptide receptor signaling, giving Semax a dual mechanism: melanocortin receptor (MC3R, MC4R, MC5R) pathways and immune-modulatory PGP receptor signaling.

Semax was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and registered as a prescription nootropic and neuroprotective drug in Russia in the 1990s. It is approved there for cognitive impairment, cerebrovascular disorders, and post-stroke recovery, administered intranasally via direct nose-to-brain transport that bypasses first-pass hepatic metabolism.

Unlike most peptides on the April 15 reclassification list, Semax has been manufactured, quality-controlled, and clinically prescribed under a regulatory framework — albeit Russia’s — for nearly three decades. This clinical history is its strongest credential and a source of methodological questions, as the Russian clinical literature does not uniformly adhere to Western trial registration and blinding standards.

What the Research Shows

Preclinical evidence is extensive and thematically diverse

The published Semax literature spans more than 25 years, with the most heavily cited work concentrated in neuroprotection, ischemia, and neurotrophin signaling:

Neurotrophin regulation. Early work demonstrated that Semax rapidly induces expression of NGF, BDNF, and NT-3 in rat glial cell cultures Neuropeptides, 2001. A 2006 study confirmed BDNF and TrkB upregulation in the rat hippocampus with measurable effects on spatial learning Brain Research, 2006.

Ischemic stroke and neuroprotection. Semax activates transcription of neurotrophin and receptor genes after cerebral ischemia in rats Molecular Biology, 2009. Transcriptome analysis revealed modulation of 150+ genes in the ischemic penumbra, including upregulation of neuroprotective factors and downregulation of pro-inflammatory mediators Genes, 2020. A 2017 study confirmed regulation of immune response genes during ischemia Mol Genet Genomics, 2017.

Alzheimer’s disease models. A 2025 study in Acta Naturae investigated Semax in an Alzheimer’s animal model, showing potential for correcting pathological impairments Acta Naturae, 2025. A 2022 study found Semax affects copper-induced amyloid-beta aggregation ACS Chem Neurosci, 2022, and the 2025 Bioinorganic Chemistry paper characterized Semax as a copper chelator that decreases Cu(II)-catalyzed ROS production and amyloid-beta cytotoxicity Bioinorg Chem Appl, 2025.

Spinal cord injury. A 2025 British Journal of Pharmacology study found that Semax targets the μ-opioid receptor gene Oprm1 to promote functional recovery after spinal cord injury in mice Br J Pharmacol, 2025.

Antidepressant and antistress effects. A 2024 study demonstrated antidepressant-like effects of Semax in the chronic mild stress model in rats, with consistent effects on behavioral despair measures Eur J Pharmacol, 2024.

Calcium dynamics. A 2025 study examined the effect of Semax on intracellular calcium dynamics in rat brain neurons, finding that the peptide modulates calcium signaling at the cellular level — relevant to its neuroprotective mechanism Bull Exp Biol Med, 2025.

Human clinical data — the Russian experience

Semax has the most extensive published human clinical experience of any peptide on the April 15 list — a direct consequence of its drug registration in Russia.

A 2018 study in the Journal of Neurology and Psychiatry evaluated Semax in patients at different stages of ischemic stroke, reporting improvements in neurological recovery Zh Nevrol Psikhiatr, 2018. Additional open-label and observational studies — predominantly Russian-language — have examined Semax for cognitive impairment in cerebrovascular disease, post-stroke recovery, traumatic brain injury, and age-related cognitive decline.

The critical limitation is the absence of large, multicenter, double-blind, placebo-controlled RCTs published in Western journals. The human data is directionally consistent but does not meet the standard required for FDA approval or what most Western clinicians would consider definitive.

Where Semax Is Most Commonly Prescribed

In the current U.S. practitioner community, Semax is most frequently prescribed for cognitive support — subjective brain fog, post-concussion cognitive complaints, or age-related memory changes. It is also used in stroke recovery protocols and increasingly for stress adaptation.

Prescription for general “cognitive enhancement” in otherwise healthy individuals is more common in the telehealth space than the evidence base supports. Clinicians should weigh the absence of modern human RCT data against the Russian clinical record of tolerability.

Legal and Regulatory Status

Pre-April 15, 2026

Semax was listed in Category 2 of the FDA’s 503A compounding framework — designated as raising significant safety concerns for compounding. Most consumer access came through the Russian-manufactured drug via personal importation or the research-chemical channel.

April 15, 2026 — Reclassification

On April 15, 2026, the FDA formally removed Semax, along with 11 other peptides, from Category 2. Licensed compounding pharmacies may now legally prepare Semax under a valid prescription. Final 503A Bulks List placement is pending the July 23–24, 2026 PCAC meeting.

July 23–24, 2026 — PCAC Outlook

The Pharmacy Compounding Advisory Committee will recommend final placement for Semax — one of seven peptides on the July agenda alongside BPC-157, TB-500, KPV, MOTS-c, DSIP, and Epitalon.

Industry expectation is cautiously favorable. Semax’s case for permanent inclusion rests on its long history of registered human use, a well-characterized safety profile, and growing international preclinical research. Scrutiny factors include limited Western clinical trial data and the absence of U.S.-standard manufacturing quality controls for the Russian-registered product. The most likely outcome is permanent inclusion with post-market surveillance.

State-Level Variance

Federal reclassification sets the floor; state pharmacy boards can set tighter rules. California, New York, Massachusetts, Connecticut, Illinois, Maryland, New Jersey, Hawaii, Vermont, and DC maintain more restrictive non-resident pharmacy regimes — expect extra verification steps in those states. See the state-by-state tracker for your jurisdiction.

The Research-Chemical Channel

The April 15 action clarifies the prescription pathway. It does not legitimize the gray market. Semax purchased from a research-chemical vendor labeled “not for human consumption” is still operating outside the legal drug supply chain — regardless of the federal reclassification.

Reported Safety Signals

Across the available Russian clinical literature and international preclinical data, Semax has a favorable reported safety profile. A 2018 safety review of Semax in ischemic stroke patients found no serious adverse events attributable to the peptide.

Reported mild adverse events include transient nasal irritation from intranasal administration (the most common delivery route in the Russian clinical context), mild headache in a small number of cases, and occasional reports of insomnia when administered too late in the day. No published reports of significant drug-drug interactions were identified.

Long-term human safety data for Semax under Western pharmacovigilance standards is absent, as it is for every peptide on the reclassification list. The longest published continuous-exposure windows in the Russian literature are measured in months, not years. The theoretical concern for a peptide that modulates neurotrophin, opioid, and melanocortin signaling pathways is the possibility of unintended long-term receptor adaptation — a risk that no published safety monitoring program has yet addressed.

Expected Pricing (Post-PCAC)

Semax’s small molecular size (7 amino acids) and straightforward peptide synthesis make it economical to manufacture at compounding quality:

Form	Expected Price Range
5mg vial (lyophilized, for reconstitution)	$80–$160
10mg vial (lyophilized)	$150–$250
30-dose intranasal spray (custom compounded)	$180–$300

Research-chemical vendors typically price 30–50% lower. That price delta reflects the absence of sterility testing, potency verification, and pharmacist oversight. Independent testing of gray-market peptides has historically shown contamination rates between 20% and 60%.

How to Source It Legitimately

Establish a relationship with a peptide-familiar prescriber (MD, DO, NP, or PA). See our provider directory.
Have a documented clinical reason. For Semax, cognitive complaints, post-stroke recovery needs, or age-related concerns provide the appropriate foundation.
Identify a legitimate compounding pharmacy licensed in your state. Use our pharmacy directory and confirm licensure in both its home state and yours.
Request a Certificate of Analysis for your specific batch — a legitimate compounder provides this without hesitation.
Verify cold-chain shipping — Semax requires refrigeration.
Maintain your supervision relationship with follow-up as your prescriber directs.

Common Questions

Is Semax FDA approved?

No. Semax is not an FDA-approved drug. It has registered drug status in Russia, where it has been prescribed since the 1990s. The April 15 action cleared the compounding path — a different status than approval.

Is Semax legal in my state?

Federal reclassification permits compounding nationwide, but state pharmacy board rules vary. Ten states and DC maintain more restrictive regimes. See our state-by-state tracker.

Is Semax safe?

Short-term safety from the Russian clinical experience is favorable. Long-term human safety data under Western pharmacovigilance standards is limited. Standard practice requires supervision by a licensed clinician.

Does Semax improve cognition?

Russian clinical and practitioner reports describe improvements in attention, memory, and executive function. The BDNF upregulation mechanism is biologically plausible. Placebo-controlled human data in healthy adults is absent.

Can I buy Semax online without a prescription?

Online vendors sell Semax as a “research chemical.” This path is not legal for human use and frequently supplies contaminated product. The legal path is prescription plus compounding pharmacy.

Semax vs. Noopept — what’s the difference?

Noopept is a synthetic dipeptide with nootropic effects also used clinically in Russia. Semax is an ACTH fragment analog with melanocortin receptor activity; Noopept is a prolyl endopeptidase inhibitor. They share no structural or mechanistic relationship.

DSIP — Another neuroactive peptide on the July 2026 PCAC agenda, studied for sleep architecture and stress response.
Epitalon — A peptide on the same regulatory timeline, studied for telomerase activation and aging-related applications.
BPC-157 — The most researched peptide on the reclassification list, studied for soft-tissue repair and gastrointestinal protection.